ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Reversal of Cisplatin Resistance in Ovarian Cancer by the Multitargeted Nanodrug Delivery System Tf-Mn-MOF@Nira@CDDP

Liu, Yuan; Wang, Yiru; Guan, Xue; Wu, Qiong; Zhang, Mengjun; Cui, Ping; Wang, Can; Chen, Xiuwei*; Meng, Xianwei*; Ma, Tengchuang*哈尔滨医科大学
ACS applied materials & interfaces2023-5-23DOI: 10.1021/acsami.3c05374
1被引10阅读
引用收藏
分享

摘要

Cisplatin (CDDP) is a widely used chemotherapeutic drugwith provenefficacy for treating tumors. However, its use has been associatedwith severe side effects and eventually leads to drug resistance,thus limiting its clinical application in patients with ovarian cancer(OC). Herein, we aimed to investigate the success rate of reversingcisplatin resistance using a synthetic, multitargeted nanodrug deliverysystem comprising a Mn-based metal-organic framework (Mn-MOF)containing niraparib (Nira) and CDDP alongside transferrin (Tf) conjugatedto the surface (Tf-Mn-MOF@Nira@CDDP; MNCT). Our results revealed thatMNCT can target the tumor site, consume glutathione (GSH), which ishighly expressed in drug-resistant cells, and then decompose to releasethe encapsulated Nira and CDDP. Nira and CDDP play a synergistic rolein increasing DNA damage and apoptosis, exhibiting excellent antiproliferation,migration, and invasion activities. In addition, MNCT significantlyinhibited tumor growth in tumor-bearing mice and exhibited excellentbiocompatibility without side effects. Furthermore, it depleted GSH,downregulated multidrug-resistant transporter protein (MDR) expression, and upregulated tumor suppressor protein phosphataseand tensin homolog (PTEN) expression, consequentlyreducing DNA damage repair and reversing cisplatin resistance. Theseresults indicate that multitargeted nanodrug delivery systems canprovide a promising clinical approach to overcoming cisplatin resistance.This study provides an experimental basis for further investigationinto multitargeted nanodrug delivery systems to reverse cisplatinresistance in patients with OC.

学科与关键词

关键词
ovarian cancercisplatin resistanceniraparibglutathionemetal-organic framework
相关
加载中…
  • cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer
    Liang, Xiaomei; Yang, Yulu; Huang, Chuanqing; Ye, Zhibin; Lai, Wujiang; Luo, Jiamao; Li, Xiaoxuan; Yi, Xiao; Fan, Jun-Bing*; Wang, Ying; Wang, Yifeng*Journal of Controlled Release, 2023, 356: 691-701.被引 4
  • A nanocomposite competent to overcome cascade drug resistance in ovarian cancer via mitochondria dysfunction and NO gas synergistic therapy
    Zhong, Min; Liang, Peiqin; Feng, Zhenzhen; Yang, Xin; Li, Guang; Sun, Rui; He, Lijuan; Tan, Jinxiu; Xiao, Yangpengcheng; Yu, Zhiqiang*; Yi, Muhua*; Wang, Xuefeng*Asian Journal of Pharmaceutical Sciences, 2023, 18(6): 100872.
  • Self-assembly nanoplatform of platinum (IV) prodrug for enhanced ovarian cancer therapy
    Ma, Xiao; Liu, Yangjia; Wu, Hanmei; Tan, Jinxiu; Yi, Wenying; Wang, Zhenjie*; Yu, Zhiqiang*; Wang, Xuefeng*Materials Today Bio, 2023, 21: 100698.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
ACS applied materials & interfaces
发表日期
2023-05-23
卷期
第 15 卷, 第 22 期
页码
26484-26495
DOI
10.1021/acsami.3c05374
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82172041, 81772274, 81801808, 82073239]; Harbin Medical University Cancer Hospital Haiyan Foundation [JJZD202101]; National Key R&D Program of China [2020YFE0100200]; Heilongjiang Postdoctoral Fund [LBH-TZ2018]

作者

  • L

    Liu, Yuan (第一作者)

    harbin med univ

  • W

    Wang, Yiru

    harbin med univ

查看全部 10 位作者收起作者
  • G

    Guan, Xue

    2 · harbin med univ

  • W

    Wu, Qiong

    chinese acad sci, tech inst phys & chem

  • Z

    Zhang, Mengjun

    harbin med univ

  • C

    Cui, Ping

    harbin med univ

  • W

    Wang, Can

    harbin med univ

  • C

    Chen, Xiuwei (通讯)

    harbin med univ

  • M

    Meng, Xianwei (通讯)

    chinese acad sci, tech inst phys & chem

  • M

    Ma, Tengchuang (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417